J

James R. Bischoff

Roche (Switzerland)

Publishes on Melanoma and MAPK Pathways, Prostate Cancer Treatment and Research, Cancer, Lipids, and Metabolism. 118 papers and 8.2k citations.

118Publications
8.2kTotal Citations

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Cited by 1.8k

The human adenovirus E1B gene encodes a 55-kilodalton protein that inactivates the cellular tumor suppressor protein p53. Here it is shown that a mutant adenovirus that does not express this viral protein can replicate in and lyse p53-deficient human tumor cells but not cells with functional p53. Ectopic expression of the 55-kilodalton EIB protein in the latter cells rendered them sensitive to infection with the mutant virus. Injection of the mutant virus into p53-deficient human cervical carcinomas grown in nude mice caused a significant reduction in tumor size and caused complete regression of 60 percent of the tumors. These data raise the possibility that mutant adenoviruses can be used to treat certain human tumors.

Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.
James R. Bischoff, Paula N. Friedman, D R Marshak et al.|Proceedings of the National Academy of Sciences|1990
Cited by 352Open Access

The human anti-oncoprotein p53 is shown to be a substrate of cdc2. The primary site of phosphorylation is serine-315. Serine-315 is phosphorylated by both p60-cdc2 and cyclin B-cdc2 enzymes. The phosphorylation of p53 is cell cycle-dependent. The abundance of p53 also oscillates during the cell cycle. The protein is largely absent from cells that have just completed division but accumulates in cells during G1 phase. Phosphorylation by cdc2 might regulate the antiproliferative activity of p53.